Abstract: A molecular structure comprising a targeting moiety, a multi-functional peptide platform and a plurality of controllably released bioactive agents attached thereto is provided herein.
Type:
Grant
Filed:
November 5, 2019
Date of Patent:
April 26, 2022
Assignee:
Ariel-University Research and Development Company Ltd.
Abstract: Adsorptive media for chromatography, particularly ion-exchange chromatography, derived from a shaped fiber. In certain embodiments, the functionalized shaped fiber presents a fibrillated or ridged structure which greatly increases the surface area of the fibers when compared to ordinary fibers. Also disclosed herein is a method to add surface pendant functional groups that provides cation-exchange or anion-exchange functionality to the high surface area fibers. This pendant functionality is useful for the ion-exchange chromatographic purification of biomolecules, such as monoclonal antibodies (mAbs).
Type:
Grant
Filed:
August 15, 2017
Date of Patent:
April 19, 2022
Assignee:
EMD Millipore Corporation
Inventors:
David Yavorsky, John Amara, Joaquin Umana, William Cataldo, Mikhail Kozlov, Matthew Stone
Abstract: The present disclosure pertains to compositions comprising anti-VEGF proteins and methods for producing such compositions in chemically defined media to reduce amounts of certain Aflibercept variants.
Type:
Grant
Filed:
September 29, 2021
Date of Patent:
April 12, 2022
Assignee:
Regeneron Pharmaceuticals, Inc.
Inventors:
Andrew Tustian, Ankit Vartak, Thomas Daly, Erica Pyles, Nisha Palackal, Shunhai Wang, Ning Li
Abstract: SPINK2 mutant peptide conjugates are provided that inhibit KLK5. The KLK5 inhibitory peptide conjugates are Fc fusion peptides in which, in certain embodiments, the Fc region of the fusion peptides are the Fc region of human IgG1 or a fragment thereof. The KLK5 inhibitory peptide conjugates include an amino acid sequence of one of SEQ ID NOs: 34, 36, 38, 40, 42, 44, 46, 48, 96, 50, 52, 54, 56, 58, or 60. Pharmaceutical compositions that include the KLK5 inhibitory peptide conjugates useful for treating KLK5-related diseases are also provided.
Abstract: In some aspects, the present invention provides compositions and methods (e.g. methods of treating, preventing, making, etc.) comprising compstatin analogs. In some embodiments, compstatin analogs comprise a linear PEG moiety having a molecular weight of 40 kDa and coupled to each of two compstatin analog moieties; wherein each compstatin analog moiety is a CA28-AEEAc-Lys moiety, the linear PEG moiety is coupled to the Lys side chain of each CA28-AEEAc-Lys moiety via a carbamate and each CA28-AEEAc-Lys moiety is Ac-Ile-Cys*-Val-(1Me)Trp-Gln-Asp-Trp-Gly-Ala-His-Arg-Cys*-Thr-[NH-CH2CH2OCH2CH2OCH2-C(?O)]-Lys-NH2 (SEQ ID NO: 51); wherein the Cys* groups are joined by a disulfide bond.
Abstract: There is provided a range of novel compounds. These novel compounds may demonstrate abroad spectrum antibacterial and antifungal activity. These compounds may be active against the emerging polymyxin resistant bacteria. These compounds may also be useful when used in conjunction with other pharmaceutically active agents.
Type:
Grant
Filed:
November 2, 2018
Date of Patent:
March 22, 2022
Assignee:
THE UNIVERSITY OF QUEENSLAND
Inventors:
Matthew Cooper, Mark Blaskovich, Alejandra Gallardo-Godoy, Karl Hansford, Alysha Elliott, Craig Muldoon, Bernd Becker
Abstract: The present invention relates to a self-assembling polypeptide, such as a spider silk polypeptide, for use as a coating material to form a uniform coating around an implant for the purpose of reducing or preventing capsular fibrosis associated with the use of such an implant in the human body.
Type:
Grant
Filed:
October 11, 2019
Date of Patent:
March 15, 2022
Assignee:
Amsilk GmbH
Inventors:
Axel Leimer, Lin Romer, Nathalie Maksimovikj
Abstract: The present invention provides lyophilized formulations of active agents, particularly of TAT-NR2B9c, as chloride salts. TAT-NR2B9c has shown promise for treating stroke, aneurysm, subarachnoid hemorrhage and other neurological or neurotraumatic conditions. The chloride salt of TAT-NR2B9c shows improved stability compared with the acetate salt form of prior formulations. Formulations of the chloride salt of TAT-NR2B9c are stable at ambient temperature thus facilitating maintenance of supplies of such a formulation in ambulances for administration at the scene of illness or accident or in transit to a hospital.
Abstract: The present invention provides methods for producing a lyophilized degarelix product which, upon reconstitution with water for injection in an amount of 20 mg/ml, shows a viscosity of up to 15 mPas. The present invention also provides a lyophilized degarelix drug substance which shows, upon dissolution in water in an amount of 20 mg/ml, a viscosity of up to 3.2 mPas, and processes for providing this lyophilized degarelix drug substance.
Type:
Grant
Filed:
July 30, 2020
Date of Patent:
March 1, 2022
Assignee:
Ferring B.V.
Inventors:
Grégoire Schwach, Anders Nilsson, Tine Elisabeth Gottschalk Bøving, Jon Holbech Rasmussen, Birgitta Mörnstam, Anders Tsirk, Ulf Annby, Jens Fomsgaard
Abstract: The present invention provides a recombinant protein or a derivative thereof, wherein the recombinant protein has an amino acid sequence of the N-terminal portion of CC chemokine receptor 4 (CCR4). The invention also provides the use of the recombinant protein or a derivative thereof for treating or preventing a disease or condition associated with CCR4 signaling, such as an allergic disease, inflammatory enteritis, psoriasis, an inflammatory skin disease, vasculitis, spondyloarthropathy, scleroderma, asthma, a respiratory allergic disease, an autoimmune disease, graft rejection, leukemia, lymphoma, a blood-borne cancer, a disease requiring inhibition of undesirable inflammation, and a cancer.
Type:
Grant
Filed:
November 14, 2018
Date of Patent:
February 22, 2022
Assignee:
Institute of Biophysics, Chinese Academy of Sciences
Abstract: The present invention provides an agent, or composition containing an agent, for use in treating or preventing hypercytokinemia in a subject resulting from cytokine release from non-proliferating immune cells in blood, wherein the agent comprises: (i) an oligopeptidic compound comprising a PCNA interacting motif and a domain that facilitates the cellular uptake of said compound, wherein the PCNA interacting motif is X1X2X3X4X5 (SEQ ID NO: 1) and wherein: X1 is a basic amino acid; X2 is an aromatic amino acid; X3 is an uncharged amino acid other than an aromatic amino acid, Glycine (G) and Proline (P); X4 is any amino acid other than Proline (P), an acidic amino acid or an aromatic amino acid; and X5 is a basic amino acid or Proline (P); or (ii) a nucleic acid molecule comprising a sequence encoding the oligopeptidic compound of (i). In certain aspects the agent and compositions of the invention may be used as single agents.
Type:
Grant
Filed:
November 13, 2019
Date of Patent:
February 15, 2022
Assignee:
Norwegian University of Science and Technology
Abstract: The present invention relates to compositions and methods for modulating or detecting allergy in a subject. The invention may be used to reduce allergenicity of compositions, such as food products, or to stimulate immunogenicity of products, such as vaccines by removal of cationic proteins resulting from transcription infidelity. The invention may be used in any mammal such as human.
Type:
Grant
Filed:
March 20, 2017
Date of Patent:
February 1, 2022
Assignee:
GENCLIS
Inventors:
Bernard Bihain, Virginie Ogier, Marie Brulliard, Sandrine Jacquenet, Benoit Thouvenot, Olivier Roitel
Abstract: Methods for the treatment or prevention of disease, such as fatty liver disease and obesity, are described including the modulation the amount of CTRP1 in a subject. Novel mouse strains are also described.
Abstract: The present invention provides a peptide of formula (I), or a pharmaceutically acceptable salt thereof, wherein the N-terminal group of the peptide is a monoradical of formula —NHR1; the C-terminal group of the peptide is a monoradical of formula —C(O)—R2; R1 is a monoradical selected from hydrogen and —C(O)—(C1-C20)alkyl; R2 is a monoradical selected from —OH and —NR3R4 radical; R3 and R4 are independently selected from hydrogen and (C1-C10)alkyl; “a” to “j” are integers from 0 to 1, provided that at least one of “a” to “j” is 1; and X1 represents any amino acid. The present invention also provides conjugates and compositions comprising the peptide of formula (I). The peptide can be used in the treatment or prevention of neoplastic diseases such as pancreatic cancer.
Abstract: The present invention relates to variants of factor IX (F.IX) or activated factor IX (F.IXa), wherein the variant is characterized in that it has clotting activity in absence of its cofactor. The present invention furthermore relates to variants of factor IX (F.IX) or activated factor IX (F.IXa), wherein the variant is characterized in that it has increased F.IX clotting activity compared to wildtype. The present invention furthermore relates to the use of these variants for the treatment and/or prophylaxis of bleeding disorders, in particular hemophilia A and/or hemophilia B or hemophilia caused or complicated by inhibitory antibodies to F.VIII. The present invention also relates to further variants of factor IX (F.IX) which have desired properties and can, thus be tailored for respective specific therapeutic applications.
Abstract: The present disclosure features signal-regulatory protein ? (SIRP-?) polypeptides and constructs that are useful, e.g., to target a cell (e.g., a cancer cell or a cell of the immune system), to increase phagocytosis of the target cell, to eliminate immune cells such as regulatory T-cells, to kill cancer cells, to treat a disease (e.g., cancer) in a subject, or any combinations thereof. The SIRP-? constructs include a high affinity SIRP-? D1 domain or variant thereof that binds CD47 with higher affinity than a wild-type SIRP-?. The SIRP-? polypeptides or constructs include a SIRP-? D1 variant fused to an Fc domain monomer, a human serum albumin (HSA), an albumin-binding peptide, or a polyethylene glycol (PEG) polymer. Compositions provided herein include (i) a polypeptide including a signal-regulatory protein ? (SIRP-?) D1 variant and (ii) an antibody.
Type:
Grant
Filed:
March 20, 2020
Date of Patent:
December 28, 2021
Assignee:
ALX Oncology Inc.
Inventors:
Jaume Pons, Bang Janet Sim, Steven Elliot Kauder, Hong Wan, Tracy Chia-Chien Kuo
Abstract: Among other things, the present disclosure provides technologies for modulating functions of beta-catenin. In some embodiments, the present disclosure provides stapled peptides that interact with beta-catenin. In some embodiments, provided stapled peptides interact with beta-catenin at an Axin-binding site of beta-catenin. In some embodiments, the present disclosure provides compounds, compositions and methods for preventing and/or treating conditions, disorders and diseases that are associated with beta-catenin.
Type:
Grant
Filed:
September 7, 2018
Date of Patent:
December 14, 2021
Assignee:
FOG PHARMACEUTICALS, INC.
Inventors:
Gerard Hilinski, So Youn Shim, Matthew Reiser Patton, John Hanney McGee, Paula Ortet, Gregory L. Verdine
Abstract: The disclosure features non-irritating pharmaceutical compositions containing CD101 in pharmaceutical acceptable salt (e.g., CD101 acetate) or neutral form. The pharmaceutical compositions can be intravenously administered to a subject to treat fungal infections (e.g., candidiasis) in the subject.
Type:
Grant
Filed:
July 11, 2018
Date of Patent:
December 14, 2021
Assignee:
Cidara Therapeutics, Inc.
Inventors:
Kenneth Bartizal, Paul Daruwala, David Hughes, Martin Patrick Hughes, Navdeep B. Malkar, Balasingam Radhakrishnan, Anuradha Vaidya
Abstract: The present invention provides a pharmaceutical formulation comprising LL-37 or a pharmaceutically-acceptable salt thereof and one or more pharmaceutically-acceptable diluent or carrier system, for use in a method of treatment of a chronic ulcer wound (such as a hard-to-heal venous leg ulcer or a diabetic foot ulcer), which method comprises: (a) topical application of the formulation to the ulcer; followed by (b) application of a dressing, and wherein the application of the formulation provides for a dose of LL-37 at the wound site that is below about 80 ?g of LL-37 applied per cm2 of wound area, and/or below about 26.7 ?g of LL-37 applied per cm2 of wound area, per day of treatment.
Type:
Grant
Filed:
June 4, 2020
Date of Patent:
December 7, 2021
Assignee:
Promore Pharma AB
Inventors:
Alvar Grönberg, Christine Dieterich, Margit Mahlapuu
Abstract: This invention features new compositions and methods that are useful in treating a host with a Gram-negative bacterial infection. Combination therapies comprising an aminocoumarin compound and a polymyxin compound are disclosed, including certain combinations that exhibit synergistic effects. Furthermore, aminocoumarin compounds are described having altered inhibition of DNA gyrase in Gram-negative bacteria and/or the ability to target the transport proteins responsible for assembling lipopolysaccharide in the outer membrane of Gram-negative bacteria.
Type:
Grant
Filed:
July 16, 2018
Date of Patent:
December 7, 2021
Assignees:
President and Fellows of Harvard College, The Ohio State University
Inventors:
Daniel E. Kahne, Michael D. Mandler, Vadim Baidin, Natividad Ruiz